Parkinson’s Disease Mouse Models
Perform in vivo efficacy studies using one of InnoSer’s Parkinson’s Disease Mouse Models
Your Preclinical Parkinson’s Disease Research with InnoSer
✓ Behavioral & Cognitive Tests
✓ Smart Pathological Assessments
✓ Fast Study Initiation
✓ Tailored Study Designs
✓ Dedicated Research Co-oridnators
As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Parkinson’s disease mouse models that are relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs. InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
InnoSer offers multiple Parkinson’s disease mouse models for preclinical research, including MPTP mouse model of Parkinson’s disease, and transgenic alpha-synuclein or seeding alpha synuclein mouse models using recombinant and/or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of Alzheimer’s disease, we recommend you discuss the most appropriate model with our neurology study directors.
InnoSer’s Available Parkinson’s Disease Mouse Models
In Vitro Neurology Assays
Screen your lead candidate compounds using InnoSer’s in vitro neurology assays to progress to preclinical in vivo studies with confidence
MPTP Mouse Model of Parkinson's Disease
InnoSer offers unique services using MPTP-based inducible PD models.
Seeding Alpha-Synuclein Models
InnoSer has extensive experience with alpha-synuclein seeding mouse models using both PD patient-derived brain and recombinant seeds.
Transgenic Alpha-Synuclein Models
InnoSer offers fee-for-service transgenic alpha-synuclein mouse models.
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
The People Behind Your Research
Sofie Carmans, PhD
Principal Scientist Neurology
Thomas Vogels, PhD
Principal Scientist Neurology
Struggling with getting your therapeutics across the blood-brain-barrier?
Discover how SonoCloud® ultrasound-mediated BBB disruption can improve brain uptake — without altering your compound.
Frequently Asked Questions
What is the best animal model for Parkinson's disease?
There is no single “best” animal model for Parkinson’s disease. In preclinical neurology CRO studies, the most appropriate Parkinson’s disease mouse model depends on the mechanistic hypothesis of the compound, the pathological feature being targeted, and the study endpoint strategy (aggregation, neurodegeneration, inflammation, or functional readouts).
Parkinson’s disease is biologically heterogeneous, and current in vivo models each capture distinct aspects of the disease. As a result, model selection is a scientific decision rather than a hierarchy of “better” or “worse” systems.
At InnoSer, we routinely support study design across all of these Parkinson’s disease mouse model platforms as part of our preclinical neurology CRO services, helping align model selection with therapeutic mechanism and regulatory-relevant endpoints.
Stay Curious: More Articles to Explore
STXBP1 Foundation and InnoSer validate R122X, a patient-variant mouse model of STXBP1 encephalopathy, to help expand therapeutic opportunities in STXBP1 research
Gene therapies, antisense oligonucleotides (ASOs), RNA editing technologies, and other precision medicine approaches are rapidly transforming the therapeutic landscape for STXBP1 encephalopathy. Currently, around 16 candidate therapies are in development across five...
![Cognitive profiling in the APP[V717I]xTau[P301S] mouse model](https://www.innoserlaboratories.com/wp-content/uploads/2026/07/Figure-1-MWM.png)
Cognitive profiling in the APP[V717I]xTau[P301S] mouse model
In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...
![Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice
In this month’s newsletter, we highlight and build upon our knowledge working with the Tau[P301S] mouse model (originally described by Allen et al., 2002), and its applicability in preclinical research.Female and male...
Clinically relevant biomarker panels for comprehensive efficacy studies in Alzheimer’s Disease mouse models
InnoSer's validated Alzheimer's disease (AD) mouse models are equipped with translationally relevant biomarker readout panels — spanning amyloid-beta (Aβ) species, phosphorylated Tau isoforms, and the early, sensitive hallmark of neurodegeneration, neurofilament light...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. InnoSer’s facilities in the Netherlands and Belgium have been AAALAC-accredited since 2016 and 2020, respectively. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com